Curriculum Vitae

Scopus ID: 10639186000

Dr. Buldini is an Assistant Professor of Pediatrics at the Women and Child Health Department, Division of Pediatric Hematology, Oncology and Stem Cell Transplant of the Padua University and Hospital since March 2010. She obtained her degree in Medicine at the University of Padua in 1998, Specialization in Pediatrics in 2004 and PhD in Development Medicine and Programming Science, Haemato-Oncology and Immunology in 2008. She performed a clinical track at the Clinic of Pediatric Hematology-Oncology, with special interest on hemopoietic stem cell transplantation, IRCCS Policlinico San Matteo, University of Pavia, in 2005-2006. She works as Paediatric Hematologist at the Clinic of Pediatric Hematology-Oncology, Maternal and Child Health Department, University of Padua, since 2006. Her clinical and research activities focus on childhood acute leukemias. She is the PI of the Morphology and Multiparametric Flow Cytometry (MFC) group at the diagnostic lab of the division of Pediatric Hematology, Oncology and Stem Cell Transplant of the Padua University and Hospital, AIEOP reference Laboratory for diagnosis (immunophenotyping and DNA index) of childhood acute leukemias, lymphomas, and assessment of Minimal Residual Disease (MRD) by MFC. She is for Responsible for immunophenotypic diagnosis and MFC-MRD in ALL at first diagnosis (AIEOP-BFM ALL trials), at Relapse (InterALL 2010), Infant ALL and AML (AIEOP LAM 2013). She is Member of AIEOP-BFM Flow Network that includes the principal national centralized Laboratories belonging to BFM and AIEOP, for standardization of immunophenotype at Diagnosis and MFC-MRD in childhood ALL. She coordinates with Prof Dworzack (Vienna) the AIEOP-BFM-AML Flow MRD group, with the collaborative project to standardize MFC-MRD in pediatric AML (since 2011). She is delegate with Prof Dworzack (Vienna) by European pediatric AML study groups (that includes the international groups BFM, NOPHO, LAME, AIOEP, DCOG, BSPHO, UK) for definition of “Response to treatment/ MRD Immunophenotyping” in AML, by Immunophenotype (since 2012). She leads the Padua Lab as AIEOP BFM partner unit in the training by MFC of ALLIC Labs, groups with limited economic resources that use essentially FC for monitoring MRD in ALL treatment (Argentina and Georgia).
She is Tutor in the “FlowInLab project” [ ], Moodle-based web site developed in collaboration with DLM Office, University of Padua as a Flow Cytometry training service. She is Member of the Trial Steering Committee of AIEOP-BFM ALL 2017 protocol (since 2018) and of the Trial Steering Committee of AIEOP-BFM AML 2020 protocol (since 2019). She is Member of the Directive Board of the AIEOP, Member of the AIEOP GdL (Gruppo di Lavoro) “Biologia Cellulare e Molecolare” (since 2009), Consultant of the AIEOP GdL “LAnL (Leucemie Acute non Linfoblastiche)” (since 2012) and Consultant of the AIEOP GdL “LAL (Leucemie Acute Linfoblastiche)” (since 2018). She is the Principal Investigator for AIEOP of the project by Ponte di Legno group on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (since 2019) and the Coordinator for AIEOP of the project by Ponte di Legno group on International large-scale study of gamma-delta receptor–positive T-cell acute lymphoblastic leukemia (since 2019). Her academic activity involves teaching Pediatrics, being an active member of Department Board, and supervision of graduate and PhD students. She is Member of Editorial Board (Review Editor) for the journal Pediatric Hematology and Hematological Malignancies, Frontiers in Pediatrics.
Publications: 54 papers. Citations: H-index of 18 (Scopus).


Latest pubblications: Click here

Related Laboratories

Immunophenotypic Plasticity of Pediatric B Acute Lymphoblastic Leukemia: a Genomic Study

We identified a new subtype of pediatric BCP-ALL, characterized by aberrant expression of antigen CD371 (CD371+) at diagnosis...

Advanced diagnostics and target discovery in all

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. It has an overall survival of approximately 80%, with certain subsets experiencing greater than 98% cure rate...